Maximizing Maxamine

Maxim Pharmaceuticals Inc. (MAXM; SSE:MAXM) believes that its Maxamine histamine immune stimulant ultimately will enjoy a broad label to treat stage IV melanoma, despite hitting the primary end point only in a subgroup of its Phase III patient population.

According to the company, not all the trial sites adhered to the protocol, which called for treatment with at least two cycles of therapy, providing a potential reason for the lack of significance in the overall population. "The primary end point in the overall population was met at sites that adhered to the protocol," said Kurt Gehlsen, chief technology officer and vice president of development...